Blinded Data Presented at CTAD Suggest that NE3107 is Biologically Active and May Have Impact on Cognitive, Biomarker, and Imaging Endpoints Among Mild to Moderate Alzheimer's Disease Patients -October 25, 2023 at 12:31 pm EDT

Statistically significant population changes from baseline were observed for all primary and secondary cognitive and functional assessments measured: ADAS-Cog12, ADCS-CGIC, MMSE, CDR, CDR-SB, ADCOMS,...

Related Keywords

Boston ,Massachusetts ,United States ,Amsterdam ,Noord Holland ,Netherlands ,Sweden ,Gothenburg ,Vastra Gotalands Lan ,Americans ,Melyssa Weible ,Bruce Mackle ,Lifesci Advisors ,Biovie Inc ,Alzheimer Disease Cooperative Study ,Elixir Health Public Relations ,International Conference On Alzheimer ,International Conference ,Globenewswire Inc ,Nasdaq ,Amyloid Probability Score ,Vie Inc ,Clinical Trials ,Clinical Outcomes ,Placebo Controlled Trial ,Moderate Probable Alzheimer ,Functional Changes From ,Disease Assessment Scale Cognitive ,Treatment Induced Epigenetic Modifications ,Probable Alzheimer ,Clinical Trial ,Related Neurological Disorders ,Investor Relations Inquiries ,Sci Advisors ,Mini Mental State Examination ,Clinical Dementia Rating ,Clinical Dementia Rating Sum ,Disease Cooperative Study Activities ,Prev Alzheimers ,Markets ,